Lorlatinib is very successful in treating ALK-positive non-small cell lung cancer, according to a phase III trial.

Published Date: 05 Jun 2024

Through a phase III clinical trial, a large group of physicians and researchers discovered that lorlatinib, an ALK inhibitor, is very effective in treating non-small cell lung cancer (NSCLC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot